文献速递骨质疏松与代谢性骨病

骨质疏松患者在地舒单抗常规实践中长期坚持治疗:36个月非干预性观察研究

Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
PubMed 文献 · Osteoporos Int · 2019-04-22

该回顾性非干预性研究分析1158例骨质疏松患者,评估36个月内接受七次地舒单抗注射的持续率(允许8周间隔),Kaplan-Meier生存分析36个月总持续率为50.7%,净持续率为64.2%,既往椎体骨折和近期骨质疏松治疗与较高持续率相关,年龄大于75岁与不持续相关。

要点

  • 36个月Kaplan-Meier持续率为50.7%,净持续率为64.2%。
  • 既往椎体骨折和近期骨质疏松治疗与较高持续率相关。
  • 年龄大于75岁与不持续相关。

核心结论

  • 该研究为目前已知最长连续观察期,提供真实世界中地舒单抗持续治疗数据。
  • 总持续率与双膦酸盐相比相当稳健,且处于既往观察期较短的地舒单抗研究的上限范围内。

研究设计与样本

  • 回顾性、非干预性研究,分析来自专科社区私人诊所的1158例患者,评估常规护理中地舒单抗的持续治疗情况。
  • 持续治疗定义为36个月内接受七次地舒单抗注射,允许8周间隔。
  • 对不持续患者进行回顾性调查,以识别停药原因(如有)。

主要发现

  • 人口学分析显示1158例患者平均年龄68.4岁,基线T值为-2.7,近一半有既往骨质疏松相关骨折。
  • Kaplan-Meier生存分析中,36个月总持续率为50.7%。
  • 净持续率(允许时间范围内接受七次注射)为队列的64.2%。
  • 多变量分析中,既往椎体骨折和近期骨质疏松治疗与较高持续率相关;年龄大于75岁与不持续相关。
  • 91.6%的不持续患者可获得停药原因,并归纳为十种最常见解释。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Persistence rates over 36 months with denosumab in patients diagnosed with osteoporosis in a real-world setting were examined, along with baseline patient characteristics predictive of persistence. This study represents the longest observational period with denosumab persistence and shows higher persistence rates when compared to bisphosphonates. INTRODUCTION: The study objective was to describe long-term persistence with denosumab among patients treated for osteoporosis in a real-world setting. We also sought to examine patient characteristics predictive of persistence. Lastly, this study attempted to place the results in context by conducting a literature review of published persistence data for denosumab. METHODS: This retrospective, non-interventional study analyzed 1158 patients from a specialty community private practice to assess patient persistence with denosumab in routine care. Persistence was defined as receiving seven denosumab injections, using an 8-week permissible gap, over 36 months. Non-persistent patients were further investigated retrospectively to identify reasons for discontinuation, when available. RESULTS: Demographic analysis showed a population of 1158 patients with mean age 68.4 years old and baseline T-score - 2.7; nearly half of which experienced a prior osteoporosis-related fracture. In a Kaplan-Meier survival analysis, 36-month persistence overall was 50.7%. Net persistence, as defined by receiving seven injections in the allowable time frame, was 64.2% of the cohort. In a multivariate analysis, prior vertebral fractures and recent osteoporosis therapy were associated with higher persistence; age greater than 75 years was associated with non-persistence. Reasons for discontinuation were available in 91.6% of non-persistent patients and categorized to include the ten most common explanations. CONCLUSION: This study to our knowledge represents the longest continuous observational period providing data on denosumab persistence in a real-world setting. The total persistence noted is quite robust when compared to bisphosphonates and is within the upper range of prior published studies of denosumab with shorter observation periods.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Borek DM, Smith RC, Gruber CN, et al. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study. Osteoporos Int. 2019. PMID: 31011760. doi:10.1007/s00198-019-04963-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。